title: Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
abstract: OBJECTIVE
  To assess the prognostic significance of nuclear receptor coactivator-3 (NCOA3) overexpression in primary cutaneous melanoma.
  
  
  METHODS
  NCOA3 expression was assessed using immunohistochemical analysis of a melanoma tissue microarray (TMA) containing primary melanomas from 343 patients with defined histology and follow-up. The impact of the presence or absence of various prognostic factors on relapse-free survival (RFS) and disease-specific survival (DSS) of melanoma patients was assessed using Cox regression and Kaplan-Meier analysis. The impact of presence or absence of various factors on sentinel lymph node (SLN) metastasis was assessed using logistic regression analysis.
  
  
  RESULTS
  Increasing degree of NCOA3 expression was significantly predictive of SLN metastasis (P = .013) and the mean number of SLN metastases (P = .031). Kaplan-Meier analysis demonstrated a significant association between NCOA3 overexpression and reduced RFS (P = .021) and DSS (P = .030). Logistic regression analysis revealed increasing degree of NCOA3 expression to be an independent predictor of SLN status (P = .017). Multivariate Cox regression analysis showed the independent impact of NCOA3 expression on RFS (P = .0095) and DSS (P = .021). NCOA3 was the most powerful factor predicting DSS, outperforming tumor thickness and ulceration.
  
  
  CONCLUSIONS
  These results identify NCOA3 as a novel, independent marker of melanoma outcome, with a significant impact on SLN metastasis, RFS, and DSS.
authors.affiliation: Auerback Melanoma Research Laboratory, Cutaneous Oncology Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA.
authors.forename: Javier
authors.initials: J
authors.lastname: Rangel
authors.forename: Sima
authors.initials: S
authors.lastname: Torabian
authors.forename: Ladan
authors.initials: L
authors.lastname: Shaikh
authors.forename: Mehdi
authors.initials: M
authors.lastname: Nosrati
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Baehner
authors.forename: Chris
authors.initials: C
authors.lastname: Haqq
authors.forename: Stanley P L
authors.initials: SP
authors.lastname: Leong
authors.forename: James R
authors.initials: JR
authors.lastname: Miller
authors.forename: Richard W
authors.initials: RW
authors.lastname: Sagebiel
authors.forename: Mohammed
authors.initials: M
authors.lastname: Kashani-Sabet
mesh_terms: D014408:Biomarkers, Tumor; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic; D051548:Histone Acetyltransferases / Q000096:biosynthesis* / Q000235:genetics*; D006801:Humans; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D056921:Nuclear Receptor Coactivator 3; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012878:Skin Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D015534:Trans-Activators / Q000096:biosynthesis* / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D015534:Trans-Activators; D051548:Histone Acetyltransferases; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3